 |
인쇄하기
취소
|
Daewoong wins patent suit against CTCBIO
Daewoong Pharm has won the right to market a medication for obesity.
The company announced on December 28 that it secured the right to sell its new anti-urinary incontinence medication on Korean market after the Korean Intellectual Property Tribunal ruled that CTCBIO’s patent lacks a novelty and should be nullified.
Daewoong developed the new medication after learning that an anti-obesity m...
The company announced on December 28 that it secured the right to sell its new anti-urinary incontinence medication on Korean market after the Korean Intellectual Property Tribunal ruled that CTCBIO’s patent lacks a novelty and should be nullified.
Daewoong developed the new medication after learning that an anti-obesity m...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.